Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CRDL
CARDIOL THERAPEUTICS INC.
NASDAQ
$1.94
▼ DOWN 5.83% (-0.12)

KEY STATISTICS

Market Cap$223.63 M
52w High$2.27
52w Low$0.88
Dividend Yield—
Frequency—
P/E-7.73
Volume1.61M
Shares Out.115.27M

COMPANY

LEADERSHIP

David G. Elsley
CHIEF EXECUTIVE
David G. Elsley

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 15, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
18

PRICE TARGET

Target High$8.00
Target Low$8.00
Target Median$8.00
Target Consensus$8.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$1.94 ▼ DOWN 5.83% (−$0.12)
$1.90$1.95$2.00$2.059:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.94

About Cardiol Therapeutics Inc.

https://www.cardiolrx.com ↗

Cardiol Therapeutics Inc. is a Canadian clinical-stage company developing anti-fibrotic and anti-inflammatory therapies, including CardiolRx, for cardiovascular diseases, COVID-19, myocarditis, and heart failure.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT CARDIOL THERAPEUTICS INC. IS KNOWN FOR

CardiolRx™
CardiolRx™

CardiolRx™ is an oral cannabidiol-based therapy in Phase III trials for recurrent pericarditis, with FDA Orphan Drug Designation, targeting anti-inflammatory and anti-fibrotic treatment for heart disease.

COMPETITORS

COMPETITOR
CAPR COMPARE
ES ESPR COMPARE
IFRX COMPARE
KNSA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
YOLO
0.76% · 281.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
25.92%
HOLDERS
79
TOP 12 OF 79 · RANKED BY POSITION SIZE
Mmcap International Inc. Spc
15.6M sh · $16.53B
Tejara Capital Ltd
5.1M sh · $6.93M
Ikarian Capital, LLC
3.3M sh · $3.52M
Boothbay Fund Management, LLC
975.7K sh · $1.03M
Citadel Advisors LLC
819.9K sh · $1.11M
Renaissance Technologies LLC
772.8K sh · $819.21K
Two Sigma Investments, LP
746.9K sh · $791.75K
Advisorshares Investments LLC
598.0K sh · $570.35K
Bank Of America Corp /De/
551.1K sh · $589.63K
Marshall Wace, Llp
544.3K sh · $582.42K
Brokers International Financial Services, LLC.
465.0K sh · $629.83K
Morgan Stanley
355.0K sh · $376.33K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
Canaccord Genuity BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
IFRX$2.23COMPARE
CNTB$2.23COMPARE
VANI$1.42COMPARE
KLRS$4.03COMPARE
HYPR$0.83COMPARE
INCR$5.78COMPARE
MBOT$1.48COMPARE
IMA$5.34COMPARE